Anti-Alzheimer's Drug, Donepezil, Markedly Improves Long-Term Survival After Chronic Heart Failure in Mice

Journal of Cardiac Failure

Volumn 15, Issue 9, 2009, Pages 805-811

  Handa, Takemi ^a   Katare, Rajesh G ^a   Kakinuma, Yoshihiko ^a   Arikawa, Mikihiko ^a   Ando, Motonori ^a   Sasaguri, Shiro ^a   Yamasaki, Fumiyasu ^a   Sato, Takayuki ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Acetylcholine; heart failure; survival; vagus nerve

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DONEPEZIL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTOCAVAL FISTULA; ARTICLE; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HEART FAILURE; INDANS; MALE; MICE; PIPERIDINES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350564898     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.05.008     Document Type: Article

References (32)

1. Li M., Zheng C., Sato T., Kawada T., Sugimachi M., and Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109 (2004) 120-124
2. Ando M., Katare R.G., Kakinuma Y., Zhang D., Yamasaki F., Muramoto K., et al. Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 112 (2005) 164-170
3. Kakinuma Y., Ando M., Kuwabara M., Katare R.G., Okudela K., Kobayashi M., et al. Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1 alpha. FEBS Lett 579 (2005) 2111-2118
4. Katare R.G., Ando M., Kakinuma Y., Arikawa M., Handa T., Yamasaki F., et al. Vagal stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect. J Thorac Cardiovasc Surg 137 (2008) 223-231
5. Sato K., Urbano R., Yu C., Yamasaki F., Sato T., Robertson D., et al. Protective effect of donepezil on cardiovascular mortality. [abstract]. Circulation 117 (2008) e269
6. Scheuermann-Freestone M., Freestone N.S., Langenickel T., Höhnel K., Dietz R., and Willenbrock R. A new model of congestive heart failure in the mouse due to chronic volume overload. Eur J Heart Fail 3 (2001) 535-543
7. Sutherland F.J., Shattock M.J., Baker K.E., and Hearse D.J. Mouse isolated perfused heart: characteristics and cautions. Clin Exp Pharmacol Physiol 30 (2003) 867-878
8. Sato T., Shishido T., Kawada T., Miyano H., Miyashita H., Inagaki M., et al. ESPVR of in situ rat left ventricle shows contractility-dependent curvilinearity. Am J Physiol Heart Circ Physiol 274 (1998) H1429-H1434
9. Kameyama T., Chen Z., Bell S.P., Fabian J., and Lewinter M.M. Mechanoenergetic studies in isolated mouse hearts. Am J Physiol Heart Circ Physiol 274 (1998) H366-H374
10. Claessens T.E., Georgakopoulos D., Afanasyeva, Vermeersch S.J., Millar H.D., et al. Nonlinear isochrones in murine left ventricular pressure-volume loops: how well does the time-varying elastance concept hold?. Am J Physiol Heart Circ Physiol 290 (2006) H1474-H1483
11. Mirsky I., Tajimi T., and Peterson K.L. The development of the entire end-systolic pressure-volume and ejection fraction-afterload relations: a new concept of systolic myocardial stiffness. Circulation 76 (1987) 343-356
12. Packer M., Coats A.J., Flowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 (1991) 293-302
14. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
15. Pitt B., Remme W., Zannad F., Neaton J., Martines F., Roniker B., et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
16. Shinke T., Takeuchi M., Takaoka H., and Yokoyama M. Beneficial effects of heart rate reduction on cardiac mechanics and energetics in patients with left ventricular dysfunction. Jpn Circ J 63 (1999) 957-964
17. Hu K., Naumann A., Fraccarollo D., Gaudron P., Kaden J.J., Neubauer S., et al. Heart rate reduction by zatebradine reduces infarct size and mortality but promotes remodeling in rats with experimental myocardial infarction. Am J Physiol Heart Circ Physiol 286 (2004) H1281-H1288
18. Nishikimi T., Hagaman J.R., Takahashi N., Kim H.S., Matsuoka H., Smithies O., et al. Increased susceptibility to heart failure in response to volume overload in mice lacking natriuretic peptide receptor-A gene. Cardiovasc Res 66 (2005) 94-103
19. Cox M.J., Hawkins U.A., Hoit B.D., and Tyagi S.C. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation 109 (2004) 2123-2128
20. Kamkin A., Kiseleva I., Wagner K.D., Pylaev A., Leiterer K.P., Theres H., et al. A possible role for atrial fibroblasts in postinfarction bradycardia. Am J Physiol Heart Circ Physiol 282 (2002) H842-H849
21. Shepherd G., Klein-Schwartz W., and Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 33 (1999) 812-815
22. Bordier P., Garrigue S., Barold S.S., Bressolles N., Lanusse S., and Clémenty J. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace 5 (2003) 429-431
23. Vanhaesebroeck B., and Alessi D.R. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res 253 (1999) 210-229
24. Rogers S.L. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dement Geriatr Cogn Disord 9 Suppl 3 (1998) 29-42
25. 1 protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 317 (2006) 606-614
26. 1 receptor. Br J Pharmacol 149 (2006) 998-1012
27. Kato K., Hayako H., Ishihara Y., Marui S., Iwane M., and Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 260 (1999) 5-8
28. Novakova M., Ela C., Barg J., Vogel Z., Hasin Y., and Eilam Y. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol 286 (1995) 19-30
29. Kekuda R., Prasad P.D., Fei Y.J., Leibach F.H., and Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 229 (1996) 553-558
30. Saxena G., Singh S.P., Agrawal R., and Nath C. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 581 (2008) 283-289
31. Auletta C.S., Mitchell J.M., Richter W.R., Taki T., and Sagami F. One-year oral toxicity study of donepezil hydrochloride in rats. Jpn Pharmacol Ther 26 Suppl 6 (1998) S1177-S1195
32. Akinci S.B., Ulu N., Yondem O.Z., Firat P., Guc M.O., Kanbak M., and Aypar U. Effect of neostigmine on organ injury in murine endotoxemia: missing facts about the cholinergic anti-inflammatory pathway. World J Surg 29 (2005) 1483-1489